Do you want to read an article? Please log in or register.
Patient involvement in rheumatoid arthritis care to improve disease activity-based management in daily practice: A randomized controlled trial
Further Publications Rheumatology
Related content
Rheumatoid Arthritis
A tailored-guided internet-based cognitive-behavioral intervention for patients with rheumatoid arthritis as an adjunct to standard rheumatological care: results of a randomized controlled trial
Pain.
Ferwerda M, van Beugen S, van Middendorp H, Spillekom-van Koulil S, Donders ART, Visser H, Taal E, Creemers MCW, van Riel PCLM, Evers AWM
doi: 10.1097/j.pain.00000000000
Rheumatoid Arthritis
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
Arthritis Care Res (Hoboken).
Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV
doi: 10.1002/acr.23004.
Rheumatoid Arthritis
Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis
Arthritis Care Res (Hoboken)
Fleischmann R, Liu J, Zhu J, Segurado OG, Furst DE
doi: 10.1002/acr.24583
COMMENTED
Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Arthritis Res Ther.
Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR
doi: 10.1186/s13075-018-1614-z.
Rheumatoid Arthritis
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
doi: 10.1016/S0140-
Rheumatoid Arthritis
Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial
Arthritis Res Ther
Jung SY, Koh JH, Kim KJ, Park YW, Yang HI, Choi SJ, Lee J, Choi CB, Kim WU
doi: 10.1186/s13075-021-02566-z
Rheumatoid Arthritis
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Arthritis Res Ther.
Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, Palaparthy R, Schumacher K, Schmitt S, Hua SY, Ianos C, Sewell KL
doi: 10.1186/s13075-018-1646-4.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Rheumatoid Arthritis
Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Z Rheumatol.
Bae SC, Lee YH
doi: 10.1007/s00393-017-0292-6.